Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra Sohal, Daniel A. Laheru, Tyler Johnson et al.|Journal of Clinical Oncology|2020Cited by 287
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancerIgnacio Garrido‐Laguna, Manuel Hidalgo|British Journal of Cancer|2010Cited by 72
Mechanisms of resistance to active state selective tri-complex RAS inhibitorsBen Sang, Piro Lito, Ling Feng Ye et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 10
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination StrategiesIda Aronchik, Mallika Singh, Sumit Kar et al.|Molecular Cancer Therapeutics|2025Cited by 1